id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0118-0029,FDA,FDA-2008-D-0118,Guidance for Industry Diabetes Mellitus - Evaluating Cariovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes - Guidance Document,Other,Guidance,2008-12-19T05:00:00Z,2008,12,,,2015-02-20T18:28:47Z,,0,0,09000064807e2e98
FDA-2008-D-0118-0028,FDA,FDA-2008-D-0118,Guidance for Industry on Diabetes Mellitus--Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes; Availability,Notice,NAD-Notice of Availability of Data,2008-12-19T05:00:00Z,2008,12,2008-12-19T05:00:00Z,,2008-12-23T23:31:51Z,E8-30086,0,0,09000064807e2c7c
FDA-2008-D-0118-0001,FDA,FDA-2008-D-0118,Draft Guidance for Industry on Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention; Availability,Notice,NAD-Notice of Availability of Data,2008-03-03T05:00:00Z,2008,3,2008-03-03T05:00:00Z,2008-05-03T03:59:59Z,2008-04-11T22:38:31Z,E8-03974,0,0,09000064803e4e6c
FDA-2008-D-0118-0002,FDA,FDA-2008-D-0118,NO DOCUMENT [See FDA-2008-D-0118-0003],Supporting & Related Material,GDL-Guidance,2008-03-03T05:00:00Z,2008,3,,,2008-04-11T22:38:31Z,,0,0,09000064803e4f5b
FDA-2008-D-0118-0003,FDA,FDA-2008-D-0118,Draft Guidance for Industry on Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention - Guidance Document,Other,GDL-Guidance (Supporting and Related Materials),2008-03-03T05:00:00Z,2008,3,2008-03-03T14:38:37Z,,2015-02-20T18:29:23Z,,0,0,09000064803e514f